Published in J Diabetes Sci Technol on January 01, 2009
Practical aspects of insulin pen devices. J Diabetes Sci Technol (2010) 1.33
Dosing accuracy and insulin flow rate characteristics of a new disposable insulin pen, FlexTouch, compared with SoloSTAR. J Diabetes Sci Technol (2013) 1.11
A Pan-European and Canadian prospective survey to evaluate patient satisfaction with the SoloSTAR insulin injection device in type 1 and type 2 diabetes. J Diabetes Sci Technol (2011) 1.09
Injection force of reusable insulin pens: Novopen 4, Lilly Luxura, Berlipen, and ClikSTAR. J Diabetes Sci Technol (2011) 1.04
Study on the dosing accuracy of commonly used disposable insulin pens. Diabetes Technol Ther (2012) 1.04
FlexTouch: a prefilled insulin pen with a novel injection mechanism with consistent high accuracy at low- (1 U), medium- (40 U), and high- (80 U) dose settings. J Diabetes Sci Technol (2011) 1.01
Biosimilar insulins: guidance for data interpretation by clinicians and users. Diabetes Obes Metab (2015) 0.89
An evaluation of prefilled insulin pens: a focus on the Next Generation FlexPen(®). Med Devices (Auckl) (2010) 0.86
Analysis of studies that compare the dose accuracy of prefilled insulin pens. J Diabetes Sci Technol (2009) 0.75
Dosing Accuracy of Insulin Aspart FlexPens After Transport Through the Pneumatic Tube System. Hosp Pharm (2013) 0.75
Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care (2005) 5.99
Needle phobia: a neglected diagnosis. J Fam Pract (1995) 3.03
NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care (1997) 2.29
Insulin delivery using pen devices. Simple-to-use tools may help young and old alike. Postgrad Med (1999) 2.18
Dosing accuracy of two insulin pre-filled pens. Curr Med Res Opin (2008) 1.85
Behavioral science in diabetes. Contributions and opportunities. Diabetes Care (1999) 1.85
Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract (1999) 1.53
Differences in the dose accuracy of insulin pens. J Diabetes Sci Technol (2008) 1.52
Prefilled insulin device with reduced injection force: patient perception and accuracy. Curr Med Res Opin (2008) 1.42
Insulin-treated diabetes patients with fear of self-injecting or fear of self-testing: psychological comorbidity and general well-being. J Psychosom Res (2001) 1.25
Evaluation of the injection force dynamics of a modified prefilled insulin pen. Expert Opin Pharmacother (2008) 1.23
Phobia of self-injecting and self-testing in insulin-treated diabetes patients: opportunities for screening. Diabet Med (2001) 1.20
Dose accuracy comparison between SoloSTAR and FlexPen at three different dose levels. Diabetes Technol Ther (2008) 1.09
Pilot study for assessment of optimal frequency for changing catheters in insulin pump therapy-trouble starts on day 3. J Diabetes Sci Technol (2010) 2.48
Clinical assessment of the accuracy of blood glucose measurement devices. Curr Med Res Opin (2012) 2.18
Psychological insulin resistance in type 2 diabetes patients regarding oral antidiabetes treatment, subcutaneous insulin injections, or inhaled insulin. Diabetes Technol Ther (2013) 2.04
Accuracy evaluation of five blood glucose monitoring systems obtained from the pharmacy: a European multicenter study with 453 subjects. Diabetes Technol Ther (2011) 1.89
Analysis of the environmental impact of insulin infusion sets based on loss of resources with waste. J Diabetes Sci Technol (2011) 1.74
Dynamic electrochemistry corrects for hematocrit interference on blood glucose determinations with patient self-measurement devices. J Diabetes Sci Technol (2011) 1.61
Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. Eur Urol (2002) 1.56
Differences in the dose accuracy of insulin pens. J Diabetes Sci Technol (2008) 1.52
Impact of insulin on microvascular blood flow and endothelial cell function in the postprandial state in patients with Type 1 diabetes. J Diabetes Complications (2005) 1.50
Review of approved pioglitazone combinations for type 2 diabetes. Expert Opin Pharmacother (2011) 1.43
Determination of nitrotyrosine concentrations in plasma samples of diabetes mellitus patients by four different immunoassays leads to contradictive results and disqualifies the majority of the tests. Clin Chem Lab Med (2009) 1.42
Association of COLIA1 Sp1 polymorphism with the effect of subcutaneously injected recombinant hGH in GH-deficient adults. Pharmacogenomics (2008) 1.39
Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol (2007) 1.38
Development and validation of a new measure to evaluate psychological resistance to insulin treatment. Diabetes Care (2007) 1.34
Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide. Nitric Oxide (2003) 1.20
Hematocrit interference of blood glucose meters for patient self-measurement. J Diabetes Sci Technol (2013) 1.18
Rearrangement analysis in archival thyroid tissues: punching microdissection and artificial RET/PTC 1-12 transcripts. J Surg Res (2007) 1.18
Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT Study. Metabolism (2007) 1.07
Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin. J Diabetes Sci Technol (2011) 1.05
Rotational stability of a single-piece hydrophobic acrylic intraocular lens: new method for high-precision rotation control. J Cataract Refract Surg (2007) 1.05
Blood glucose meters employing dynamic electrochemistry are stable against hematocrit interference in a laboratory setting. J Diabetes Sci Technol (2013) 1.01
Determination of hematocrit interference in blood samples derived from patients with different blood glucose concentrations. J Diabetes Sci Technol (2013) 1.01
Biological background and role of adiponectin as marker for insulin resistance and cardiovascular risk. Clin Lab (2005) 0.99
Short communication: high prevalence of the cytochrome P450 2C8*2 mutation in Northern Ghana. Trop Med Int Health (2005) 0.98
Coverage of postprandial blood glucose excursions with inhaled technosphere insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes. Diabetes Care (2007) 0.98
Combined application of stable carbon isotope analysis and specific metabolites determination for assessing in situ degradation of aromatic hydrocarbons in a tar oil-contaminated aquifer. Environ Sci Technol (2004) 0.98
Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk. Diab Vasc Dis Res (2008) 0.97
Detection of papillary thyroid carcinoma by analysis of BRAF and RET/PTC1 mutations in fine-needle aspiration biopsies of thyroid nodules. World J Surg (2010) 0.97
Evaluation of dexterity in insulin-treated patients with type 1 and type 2 diabetes mellitus. J Diabetes Sci Technol (2011) 0.96
ProAct study: new features of insulin pumps improve diabetes management and glycemic control in patients after transition of continuous subcutaneous insulin infusion systems. Diabetes Technol Ther (2013) 0.96
Evaluation of CGMS during rapid blood glucose changes in patients with type 1 diabetes. Diabetes Technol Ther (2006) 0.93
Intra-individual variability of the metabolic effect of a novel rapid-acting insulin (VIAject) in comparison to regular human insulin. J Diabetes Sci Technol (2008) 0.93
Comparison of patient preference for two insulin injection pen devices in relation to patient dexterity skills. J Diabetes Sci Technol (2012) 0.92
The precision study: examining the inter- and intra-assay variability of replicate measurements of BGStar, iBGStar and 12 other blood glucose monitors. Expert Opin Med Diagn (2013) 0.92
Anaerobic degradation of polycyclic aromatic hydrocarbons. FEMS Microbiol Ecol (2004) 0.91
Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study. Cardiovasc Diabetol (2011) 0.88
Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2. Microcirculation (2005) 0.88
Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer. Anticancer Drugs (2006) 0.88
Impact of pathognomonic genetic alterations on the prognosis of papillary thyroid carcinoma. ESES vienna presentation. Langenbecks Arch Surg (2010) 0.88
The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions. Diabetes Technol Ther (2008) 0.87
Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies. Diab Vasc Dis Res (2013) 0.87
Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control. Exp Diabetes Res (2012) 0.86
Peripheral leptin levels in narcoleptic patients. Diabetes Technol Ther (2007) 0.86
Changes of the speaking and singing voice after thyroid or parathyroid surgery. Surgery (2006) 0.86
Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes. Expert Opin Pharmacother (2012) 0.86
Assessment of the mixing efficiency of neutral protamine Hagedorn cartridges. J Diabetes Sci Technol (2010) 0.85
Effect of insulin glulisine on microvascular blood flow and endothelial function in the postprandial state. Diabetes Care (2008) 0.84
Increased arterial augmentation and augmentation index as surrogate parameters for arteriosclerosis in subjects with diabetes mellitus and nondiabetic subjects with cardiovascular disease. J Diabetes Sci Technol (2007) 0.84
Searching for non-RET molecular alterations in medullary thyroid carcinoma: expression analysis by mRNA differential display. World J Surg (2005) 0.83
Postprandial vascular effects of VIAject compared with insulin lispro and regular human insulin in patients with type 2 diabetes. Diabetes Care (2009) 0.83
Cytokine gene polymorphisms and the susceptibility to liver cirrhosis in patients with chronic hepatitis C. Liver Int (2003) 0.82
In type 2 diabetes patients, insulin glargine is associated with lower postprandial release of intact proinsulin compared with sulfonylurea treatment. J Diabetes Sci Technol (2012) 0.82
Endothelial function and arterial stiffness in uncomplicated type 1 diabetes and healthy controls and the impact of insulin on these parameters during an euglycemic clamp. J Diabetes Sci Technol (2007) 0.81
Identification of differentially expressed genes in papillary thyroid carcinomas with and without rearrangements of the tyrosine kinase receptors RET and/or NTRK1. J Surg Res (2005) 0.81
A class of 5-benzylidene-2-phenylthiazolinones with high potency as direct 5-lipoxygenase inhibitors. J Med Chem (2011) 0.80
Pilot study for the evaluation of morphological and functional changes in retinal blood flow in patients with insulin resistance and/or type 2 diabetes mellitus. J Diabetes Sci Technol (2012) 0.80
mRNA expression profile of matrix metalloproteinases and their tissue inhibitors in malignant and non-malignant prostatic tissue. Anticancer Res (2003) 0.80
Dose escalating safety study of CNS 5161 HCl, a new neuronal glutamate receptor antagonist (NMDA) for the treatment of neuropathic pain. Br J Clin Pharmacol (2007) 0.79
The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study. J Diabetes Sci Technol (2011) 0.79
Reliability of lightguide spectrophotometry (O2C) for the investigation of skin tissue microvascular blood flow and tissue oxygen supply in diabetic and nondiabetic subjects. J Diabetes Sci Technol (2008) 0.79
C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients. Exp Diabetes Res (2008) 0.79
Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus - results from an exploratory study. Cardiovasc Diabetol (2013) 0.78
IRIS II Study: Sensitivity and specificity of intact proinsulin, adiponectin, and the proinsulin/adiponectin ratio as markers for insulin resistance. Diabetes Technol Ther (2004) 0.78
Investigation of insulin resistance in narcoleptic patients: dependent or independent of body mass index? Neuropsychiatr Dis Treat (2011) 0.78
Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study. J Diabetes Sci Technol (2009) 0.78
Development and validation of a rapid and reliable method for TPMT genotyping using real-time PCR. Clin Lab (2012) 0.78
Patient device assessment evaluation of two insulin injection devices in a mixed cohort of insulin-treated patients with type 1 or type 2 diabetes mellitus. Curr Med Res Opin (2012) 0.78
Impact of treatment with rosiglitazone or metformin on biomarkers for insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome. J Diabetes Sci Technol (2007) 0.77
Time-action profile and patient assessment of inhaled insulin via the Exubera device in comparison with subcutaneously injected insulin aspart via the FlexPen device. Diabetes Technol Ther (2009) 0.77
The beta-specific protein kinase C inhibitor ruboxistaurin (LY333531) suppresses glucose-induced adhesion of human monocytes to endothelial cells in vitro. J Diabetes Sci Technol (2007) 0.77
Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in type 2 diabetes patients with insufficient glycemic control by metformin alone--results from a post-marketing surveillance trial under daily routine conditions. Diabetes Technol Ther (2009) 0.77
Reply to "comments on Petrak et al.'s 'psychological insulin resistance in type 2 diabetes patients regarding oral antidiabetes treatment, subcutaneous insulin injections, or inhaled insulin': considerations for language and communication". Diabetes Technol Ther (2013) 0.77
Expression and secretion of endostatin in thyroid cancer. Ann Surg Oncol (2008) 0.77
Congenital primary hypothyroidism with subsequent adenomatous goiter in a Turkish patient caused by a homozygous 10-bp deletion in the thyroid peroxidase (TPO) gene. Clin Endocrinol (Oxf) (2006) 0.77
Laboratory evaluation of a new lateral-flow-based point-of-care rapid test for assessment of chronic systemic inflammation. J Diabetes Sci Technol (2010) 0.77
Molecular effects of C-Peptide in microvascular blood flow regulation. Rev Diabet Stud (2009) 0.77
Increased prevalence of cardiovascular disease and risk biomarkers in patients with unknown type 2 diabetes visiting cardiology specialists: results from the DIASPORA study. Diab Vasc Dis Res (2010) 0.77
Transplantation of adrenal tissue fragments in a murine model: functional capacities of syngeneic and allogeneic grafts. World J Surg (2002) 0.76
Resolution of adiponectin oligomers in human plasma using free flow electrophoresis. Arch Physiol Biochem (2009) 0.76
Growth hormone dose in growth hormone-deficient adults is not associated with IGF-1 gene polymorphisms. Pharmacogenomics (2009) 0.76
Pioglitazone in addition to metformin improves erythrocyte deformability in patients with Type 2 diabetes mellitus. Clin Sci (Lond) (2010) 0.76
Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study. Atherosclerosis (2008) 0.76
Association of the exon 3 deleted/full-length GHR polymorphism with recombinant growth hormone dose in growth hormone-deficient adults. Pharmacogenomics (2009) 0.76
Pharmacokinetic and Pharmacodynamic Characteristics of Subcutaneously Applied PTH-1-37. Kidney Blood Press Res (2016) 0.76
Evaluation of the effects of insufficient blood volume samples on the performance of blood glucose self-test meters. J Diabetes Sci Technol (2013) 0.75
Elevated peripheral visfatin levels in narcoleptic patients. PLoS One (2008) 0.75
Comparison of the Effects of Pioglitazone versus Placebo when Given in Addition to Standard Insulin Treatment in Patients with Type 2 Diabetes Mellitus Requiring Hemodialysis: Results from the PIOren Study. Nephron Extra (2012) 0.75
Pioglitazone improves metabolic markers in patients with type 2 diabetes independently from physical activities: results from the IRIS III study. J Diabetes Sci Technol (2008) 0.75
Response to Jungheim and Koschinsky. Diabetes Care (2002) 0.75
Self-monitoring of blood glucose levels requires intensive training for use of meters to obtain reliable and clinically relevant measurements. J Diabetes Sci Technol (2007) 0.75